Metabolic regulation of regulatory T cell development and function

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Coe, David John ^a   Kishore, Madhav ^a   Marelli Berg, Federica ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Metabolism; mTOR pathway; Regulatory T cells; T cell differentiation; T cell function

Indexed keywords

3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; ADENOSINE TRIPHOSPHATE; CD103 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETOMOXIR; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

APOPTOSIS; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CLONAL ANERGY; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; FATTY ACID OXIDATION; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; IMMUNE RESPONSE; INTRAABDOMINAL FAT; LIPID METABOLISM; METABOLIC REGULATION; NONHUMAN; OBESITY; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84919394524     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00590     Document Type: Short Survey

References (69)

1. Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity (2007) 27:173-8. doi: 10.1016/j.immuni.2007.07.008
2. Bental M, Deutsch C. Metabolic changes in activated T cells: an NMR study of human peripheral blood lymphocytes. Magn Reson Med (1993) 29:317-26. doi:10.1002/mrm.1910290307
3. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol (2005) 5:844-52. doi:10.1038/nri1710
4. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 16:769-77. doi:10.1016/S1074-7613(02)00323-0
5. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol (2008) 180:4476-86. doi:10.4049/jimmunol.180.7.4476
6. Alves NL, Derks IA, Berk E, Spijker R, van Lier RA, Eldering E. The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity (2006) 24:703-16. doi:10.1016/j.immuni.2006.03.018
7. Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN, et al. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem (2011) 286:5921-33. doi:10.1074/jbc.M110.179101
8. Greiner EF, Guppy M, Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem (1994) 269:31484-90.
9. Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol (2007) 178:2163-70. doi:10.4049/jimmunol.178.4.2163
10. Peter C, Waldmann H, Cobbold SP. mTOR signalling and metabolic regulation of T cell differentiation. Curr Opin Immunol (2010) 22:655-61. doi:10.1016/j.coi.2010.08.010
11. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 33:301-11. doi:10.1016/j.immuni.2010.09.002
12. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell (2000) 101:455-8. doi:10.1016/S0092-8674(00)80856-9
13. Shevach EM. Regulatory T cells in autoimmmunity*. Annu Rev Immunol (2000) 18:423-49. doi:10.1146/annurev.immunol.18.1.423
14. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 2:301-6. doi:10.1038/86302
15. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 110:1225-32. doi:10.1182/blood-2006-12-064527
16. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 30:832-44. doi:10.1016/j.immuni.2009.04.014
17. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity (2010) 32:743-53. doi:10.1016/j.immuni.2010.06.002
18. Procaccini C, De Rosa V, Galgani M, Abanni L, Cali G, Porcellini A, et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity (2010) 33:929-41. doi:10.1016/j.immuni.2010.11.024
19. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol (2011) 186:3299-303. doi:10.4049/jimmunol.1003613
20. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208:1367-76. doi:10.1084/jem.20110278
21. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell (2007) 12:9-22. doi:10.1016/j.ccr.2007.05.008
22. Kane LP, Weiss A. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol Rev (2003) 192:7-20. doi:10.1034/j.1600-065X.2003.00008.x
23. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell (2007) 18:1437-46. doi:10.1091/mbc.E06-07-0593
24. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324:1029-33. doi:10.1126/science.1160809
25. Yang K, Chi H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin Immunol (2012) 24:421-8. doi:10.1016/j.smim.2012.12.004
26. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 105:4743-8. doi:10.1182/blood-2004-10-3932
27. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol (1999) 162:2775-84.
28. Vanasek TL, Khoruts A, Zell T, Mueller DL. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol (2001) 167:5636-44. doi:10.4049/jimmunol.167.10.5636
29. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 499:485-90. doi:10.1038/nature12297
30. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev (2011) 25:1895-908. doi:10.1101/gad.17420111
31. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase - development of the energy sensor concept. J Physiol (2006) 574:7-15. doi:10.1113/jphysiol.2006.108944
32. Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci (2009) 34:620-7. doi:10.1016/j.tibs.2009.09.004
33. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle (2011) 10:2305-16. doi:10.4161/cc.10.14.16586
34. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11:859-71. doi:10.1016/j.devcel.2006.10.007
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307:1098-101. doi:10.1126/science.1106148
36. Matarese G, Colamatteo A, De Rosa V. Metabolic fuelling of proper T cell functions. Immunol Lett (2014) 161:174-8. doi:10.1016/j.imlet.2013.12.012
37. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature (2007) 450:736-40. doi:10.1038/nature06322
38. Powell JD, Heikamp EB, Pollizzi KN, Waickman AT. A modified model of T-cell differentiation based on mTOR activity and metabolism. Cold Spring Harb Symp Quant Biol (2013) 78:125-30. doi:10.1101/sqb.2013.78.020214
39. Fisson S, Darrasse-Jèze G, Litvinova E, Septier F, Klatzmann D, Liblau R, et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med (2003) 198:737-46. doi:10.1084/jem.20030686
40. Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, Masters JE, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest (2006) 116:2423-33. doi:10.1172/JCI28941
41. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 188:287-96. doi:10.1084/jem.188.2.287
42. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature (1998) 394:897-901. doi:10.1038/29795
43. Barbi J, Pardoll D, Pan F. Metabolic control of the Treg/Th17 axis. Immunol Rev (2013) 252:52-77. doi:10.1111/imr.12029
44. Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity (2010) 32:54-66. doi:10.1016/j.immuni.2009.12.003
45. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol (2012) 30:39-68. doi:10.1146/annurev-immunol-020711-075024
46. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 249:43-58. doi:10.1111/j.1600-065X.2012.01152.x
47. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 12:295-303. doi:10.1038/ni.2005
48. Gabryšová L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O'Garra A. Integrated T-cell receptor and costimulatory signals determine TGF-β-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol (2011) 41:1242-8. doi:10.1002/eji.201041073
49. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol (2005) 5:712-21. doi:10.1038/nri1685
50. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146:772-84. doi:10.1016/j.cell.2011.07.033
51. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature (2012) 486:549-53. doi:10.1038/nature11132
52. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med (2009) 15:930-9. doi:10.1038/nm.2002
53. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol (2010) 72:219-46. doi:10.1146/annurev-physiol-021909-135846
54. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 15:921-9. doi:10.1038/nm.2001
55. Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, Narula V, et al. Visceral adipose inflammation in obesity is associated with critical alterations in T regulatory cell numbers. PLoS One (2011) 6:e16376. doi:10.1371/journal.pone.0016376
56. Procaccini C, Galgani M, De Rosa V, Matarese G. Intracellular metabolic pathways control immune tolerance. Trends Immunol (2012) 33:1-7. doi:10.1016/j.it.2011.09.002
57. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol (2011) 11:85-97. doi:10.1038/nri2921
58. Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol (2010) 185:1037-44. doi:10.4049/jimmunol.0903586
59. Hörig H, Spagnoli GC, Filgueira L, Babst R, Gallati H, Harder F, et al. Exogenous glutamine requirement is confined to late events of T cell activation. J Cell Biochem (1993) 53:343-51. doi:10.1002/jcb.240530412
60. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol (1998) 160:5347-54.
61. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, et al. Suppression of T-cell functions by human granulocyte arginase. Blood (2006) 108:1627-34. doi:10.1182/blood-2006-11-010389
62. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood (2009) 113:2394-401. doi:10.1182/blood-2008-07-144485
63. Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut (2010) 59:595-604. doi:10.1136/gut.2009.185108
64. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002) 168:3771-6. doi:10.4049/jimmunol.168.8.3771
65. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by d-1-methyl-tryptophan. Oncoimmunology (2012) 1:1460-8. doi:10.4161/onci.21716
66. Cobbold SP, Adams E, Farquhar CA, Nolan KF, Howie D, Lui KO, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 106:12055-60. doi:10.1073/pnas.0903919106
67. Howie D, Waldmann H, Cobbold S. Nutrient sensing via mTOR in T Cells maintains a tolerogenic microenvironment. Front Immunol (2014) 5:409. doi:10.3389/fimmu.2014.00409
68. Makki K, Taront S, Molendi-Coste O, Bouchaert E, Neve B, Eury E, et al. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS One (2014) 9:e92684. doi:10.1371/journal.pone.0092684
69. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (2013) 341:569-73. doi:10.1126/science.1241165